EVIDENCE MATRIX / FOUR DOSSIERS
Compare the Claim to the Study That Carries It
Mechanism, model, sample, endpoint, and replication reveal four different levels of confidence beneath one broad peptide label.
In plain English
These four peptides are not alternatives for one job. They sit in different biological systems and at different stages of evidence. Thymosin alpha-1 targets immune coordination and has substantial human study, but its largest sepsis trial was negative [1]. MOTS-c is a mitochondrial stress signal with detailed cell and animal data, but no human efficacy trial in this corpus [8][11][12]. BPC-157 has repair and blood-vessel-growth findings in experimental models, while the human record consists of only a few pilots [13][14][16]. Tirzepatide is a dual incretin medicine supported by large randomized trials and direct comparisons [18][21][22].
The correct comparison is therefore not “which is best.” It is “what claim can each evidence stack support?” Novel mechanisms rank high for MOTS-c and BPC-157. Clinical replication ranks highest for tirzepatide. Thymosin alpha-1 provides the most instructive correction: promising earlier results can weaken when a larger, better-controlled experiment arrives. The matrix below keeps mechanism and evidence maturity in separate columns so one cannot substitute for the other.
The evidence matrix
| Dimension | Thymosin Alpha-1 | MOTS-c | BPC-157 | Tirzepatide |
|---|---|---|---|---|
| Primary system | Innate–adaptive immune interface | Mitochondrial stress and muscle metabolism | Cytoprotection, angiogenesis, repair | GIP and GLP-1 incretin signaling |
| Key targets | TLR2/TLR9, dendritic cells, IDO [6] | AMPK/NRF2 and direct CK2 binding [8][12] | VEGFR2–Akt–eNOS [16] | GIPR and GLP-1R [19] |
| Strongest model | Large human sepsis RCT | Cells and multiple mouse models | Cell and animal models; tiny human pilots | Large phase 3 human RCTs |
| Most useful result | No mortality benefit in the largest sepsis test [1] | Muscle function and stress signaling in mice [8][11] | Pro-angiogenic repair mechanism [16] | Large weight and glucose effects [18][21][22] |
| Replication | Earlier sepsis signal not confirmed by larger phase 3 [1][5] | Converging mechanisms; human efficacy untested | Limited independent and human replication [14] | Multiple large trials and active comparisons [18][21][22] |
| Regulatory frame | Used internationally; no US marketing approval [2] | Not FDA-approved | Not FDA-approved [14] | FDA-approved prescription medicine [19] |
| Defining caution | Immune-state dependence and negative phase 3 result | Human safety and pharmacokinetics unknown | Human evidence thin; angiogenesis raises theoretical questions | GI tolerability and gallbladder/biliary signal [20][21] |
Mechanism is a map, not an outcome
Mechanistic evidence asks whether a proposed pathway is coherent. MOTS-c offers frontier novelty: stress-linked movement from mitochondria into the nucleus, AMPK-dependent gene regulation, and direct CK2 binding [8][12]. BPC-157’s VEGFR2 internalization and downstream angiogenic signaling supplies a specific repair hypothesis [16]. Thymosin alpha-1’s combination of Toll-like-receptor signaling, T-helper-1 priming, and IDO-linked regulatory T-cell generation makes “immune booster” an inadequate label [6]. Tirzepatide’s dual GIP and GLP-1 mechanism connects directly to meal-response biology [19].
None of those pathway descriptions contains a human effect size. Clinical claims require clinical studies. A target can be real while an intervention fails because exposure, disease timing, patient selection, compensatory biology, or the endpoint differs from the model. The audit keeps a pathway diagram in the hypothesis column until outcomes move in an appropriate design.
Study design changes the conclusion
The evidence ladder is visible within the set. BPC-157’s human safety pilot included two adults and observed no adverse events [13]. That result can say what happened to those participants, not define population safety or tissue-repair efficacy. MOTS-c levels were associated with outcomes in 94 hemodialysis patients, and the marker modestly improved a risk model [9]. Because the study did not randomize administration, it cannot show therapeutic benefit.
Thymosin alpha-1 supplies an internal replication test. ETASS enrolled 361 participants and suggested an absolute 28-day mortality gap of about 9 percentage points, with results near the boundary of statistical significance [5]. TESTS later enrolled 1,106 adults under double-blind placebo control and estimated a hazard ratio of 0.99, essentially no separation [1]. Tirzepatide has repeated phase 3 effects across placebo and active comparators, with participant counts ranging from 751 to 2,539 in the key trials summarized here [18][21]. Better design does not guarantee a preferred answer; it makes the answer more dependable.
Safety confidence follows the same ladder
Safety is not the inverse of reported harm. When a small study reports no events, the correct label is “few events observed in a small sample,” not “safe.” That distinction is central for BPC-157 and MOTS-c. Their limited human exposure leaves uncommon, delayed, interaction, and population-specific risks largely unmapped. Unregulated product quality creates an additional uncertainty outside the molecule itself.
Thymosin alpha-1 has a longer clinical record and is generally described as well tolerated, with local reactions prominent [2]. Its immunomodulatory mechanism still makes starting immune state relevant. Tirzepatide’s large program allows more precise statements: gastrointestinal adverse effects recur across trials [21][22], and a nine-trial meta-analysis found a significant composite gallbladder or biliary signal while pancreatitis was not significantly increased [20]. Mature evidence does not mean no risk. It means risks can be estimated and disputed with better resolution.
Four confidence labels
For thymosin alpha-1, the label is clinically studied, indication-dependent, and corrected by a negative large sepsis trial. For MOTS-c, it is mechanistically convergent and preclinical, with human association but no human intervention result. For BPC-157, it is broadly preclinical, lightly piloted in humans, and far less established than the online claim set implies. For tirzepatide, it is clinically replicated and approved, with measurable safety trade-offs.
Those labels are intentionally asymmetric. A hub that flattened all four into “promising research peptides” would discard the most useful information in the corpus. Evidence maturity is itself a finding.